

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

SEC 1473 (7-02)

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)							
1. Name and Address of Reporting Person <sup>*</sup> Looby Tom	2. Date of Event Requiring Statement (Month/Day/Year) 05/06/2015	3. Issuer Name and Ticker or Trading Symbol EKSO BIONICS HOLDINGS, INC. [EKSO]					
(Last) (First) (Middle) C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201	05/00/2015	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title Other (specify below) President and Interim CEO			5. If Amendment, Date Original Filed(Month/Day/Year) 05/06/2015		
(Street) RICHMOND, CA 94804					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City) (State) (Zip)	Table I - Non-Derivative Securities Beneficially Owned						
1. Title of Security (Instr. 4)	2. Amount of Se Beneficially Ow (Instr. 4)	ned	*	4. Natur (Instr. 5	e of Indirect Beneficial Ownership )		
Common Stock	4,200 (1)		D				

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond
unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	Expiration Date (Month/Day/Year)		Securities Underlying Derivative Security (Instr. 4)		or Exercise Price of Derivative	Form of Derivative Security:	6. Nature of Indirect Beneficia Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	· · · · ·	Direct (D) or Indirect (I) (Instr. 5)	
Employee Stock Option (right to buy)	<u>(2)</u>	02/28/2024	Common Stock	400,000	\$ 2.19	D	
Employee Stock Option (right to buy)	<u>(3)</u>	02/05/2025	Common Stock	200,000	\$ 1.39	D	

## **Reporting Owners**

Reporting Owner Name / Address		Relationships					
		10% Owner	Officer	Other			
Looby Tom C/O EKSO BIONICS HOLDINGS, INC. 1414 HARBOUR WAY SOUTH, SUITE 1201 RICHMOND, CA 94804			President and Interim CEO				

### **Signatures**

/s/ Michelle L. Basil, as attorney in fact Signature of Reporting Person 03/03/2016

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

(1) The reporting person's original Form 3 inadvertenly omitted 200 shares of Common Stock.

- (2) The option became exercisable as to 25% of the total number of shares on February 28, 2015 and thereafter vests in equal monthly installments for 36 months.
- (3) The option becomes exercisable as to 25% of the total number of shares on February 5, 2016 and thereafter vests in equal monthly installments for 36 months.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.